Sunshine Operating Cycle from 2010 to 2026

SBFM Stock  USD 1.17  0.02  1.74%   
Sunshine Biopharma Operating Cycle yearly trend continues to be very stable with very little volatility. Operating Cycle is likely to grow to 234.38 this year. During the period from 2010 to 2026, Sunshine Biopharma Operating Cycle quarterly data regression pattern had sample variance of  147,911 and median of  532.96. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
189.51
Current Value
234.38
Quarterly Volatility
384.59208566
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 9.6 K, Other Operating Expenses of 49.1 M or Total Operating Expenses of 19.9 M, as well as many indicators such as Price To Sales Ratio of 0.066, Dividend Yield of 0.0 or PTB Ratio of 0.0979. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
  
Build AI portfolio with Sunshine Stock
Check out the analysis of Sunshine Biopharma Correlation against competitors.
To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.
Evaluating Sunshine Biopharma's Operating Cycle across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Sunshine Biopharma's fundamental strength.

Latest Sunshine Biopharma's Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Sunshine Biopharma over the last few years. It is Sunshine Biopharma's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sunshine Biopharma's overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

Sunshine Operating Cycle Regression Statistics

Arithmetic Mean357.51
Geometric Mean437.30
Coefficient Of Variation107.57
Mean Deviation286.29
Median532.96
Standard Deviation384.59
Sample Variance147,911
Range1.2K
R-Value(0.33)
Mean Square Error140,694
R-Squared0.11
Significance0.20
Slope(25.06)
Total Sum of Squares2.4M

Sunshine Operating Cycle History

2026 234.38
2025 189.51
2024 210.56
2023 171.53
2022 613.91
2021 339.73
2020 345.48

About Sunshine Biopharma Financial Statements

Sunshine Biopharma investors utilize fundamental indicators, such as Operating Cycle, to predict how Sunshine Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Cycle 189.51  234.38 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Sunshine Biopharma is a strong investment it is important to analyze Sunshine Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sunshine Biopharma's future performance. For an informed investment choice regarding Sunshine Stock, refer to the following important reports:
Check out the analysis of Sunshine Biopharma Correlation against competitors.
To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Will Biotechnology sector continue expanding? Could Sunshine diversify its offerings? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sunshine Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(15.02)
Revenue Per Share
14.633
Quarterly Revenue Growth
0.012
Return On Assets
(0.11)
Return On Equity
(0.26)
Investors evaluate Sunshine Biopharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Sunshine Biopharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Sunshine Biopharma's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Sunshine Biopharma's market price signifies the transaction level at which participants voluntarily complete trades.